Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons dr. M. (Hilde) Jalving

Publicaties

128P - Whole blood transcriptomics identifies transcriptional patterns linked to outcomes in patients receiving immune checkpoint inhibitors

B cells critical for outcome in high grade serous ovarian carcinoma

Causality and functional relevance of BRCA1 and BRCA2 pathogenic variants in non-high-grade serous ovarian carcinomas

Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol

Environmentally sustainable prescribing: recommendations for EU pharmaceutical legislation

Everolimus decreases [U-13C]glucose utilization by pyruvate carboxylase in breast cancer cells in vitro and in vivo.

Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement

Immune Checkpoint Inhibitors in Endometrial Cancer: A Cinderella Story

Long-term outcome of high-grade serous carcinoma established in risk-reducing salpingo-oophorectomy specimens in asymptomatic BRCA1/2 germline pathogenic variant carriers

Long-Term Survival in Patients With Advanced Melanoma

Lees meer

Pers/media

MEDtalks - Melanoomupdate 2024

Environmental impact to be included in package leaflets accompanying medication

European Oncologists Are Thinking Green

“Green” prescribing may limit the environmental impact of oncology

MEDtalks E-learning; Zeldzame melanomen en huidtumoren

Lees meer